Document is current
Any future updates will be listed below
-
Authors
Parker, Victoria E. R. https://orcid.org/0000-0003-2706-2669
Robertson, Darren
Erazo-Tapia, Edmundo
Havekes, Bas
Phielix, Esther https://orcid.org/0000-0002-2672-0415
de Ligt, Marlies
Roumans, Kay H. M. https://orcid.org/0000-0003-0666-2147
Mevenkamp, Julian
Sjoberg, Folke
Schrauwen-Hinderling, Vera B. https://orcid.org/0000-0001-7795-584X
Johansson, Edvin https://orcid.org/0000-0003-2515-2054
Chang, Yi-Ting
Esterline, Russell
Smith, Kenneth
Wilkinson, Daniel J.
Hansen, Lars
Johansson, Lars https://orcid.org/0000-0001-5954-3497
Ambery, Philip https://orcid.org/0000-0003-2978-1886
Jermutus, Lutz https://orcid.org/0000-0001-7660-8467
Schrauwen, Patrick https://orcid.org/0000-0002-0973-847X
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 31 January 2023
Accepted: 31 October 2023
First Online: 8 December 2023
Competing interests
: This study was funded by AstraZeneca. V.B.S.-H. was supported by a European Research Council starting grant (no. 759161, MRS in Diabetes). Medical writing support was provided by C. Foster, Oxford PharmaGenesis, which was funded by AstraZeneca. V.E.R.P., D.R., Y.-T.C., R.E., L.H., P.A. and L. Jermutus are employees and stockholders of AstraZeneca. E.J. is an employee of Antaros Medical. L. Johansson is an employee and stockholder of Antaros Medical. P.S. has received institutional research funding from AstraZeneca. The other authors declare no conflicts of interest.
